B of A Securities Downgrades Beam Therapeutics to Neutral, Announces $35 Price Target
B of A Securities Downgrades Beam Therapeutics to Neutral, Announces $35 Price Target
A股銀行將Beam Therapeutics的評級下調至中性,宣佈35美元的目標股價
B of A Securities analyst Greg Harrison downgrades Beam Therapeutics (NASDAQ:BEAM) from Buy to Neutral and announces $35 price target.
Bof A證券分析師格雷格·哈里森將Beam Therapeutics(納斯達克股票代碼:BEAM)的評級從買入下調至中性,並宣佈了35美元的目標股價。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。